Be willing to return to the center for all study-related follow up procedures, including blood collections and completion of imaging studies as required by the protocol
Patients with inability to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
Able to return for treatment and follow-up on the specified days
Patients with inability to return for follow-up visits to assess toxicity to therapy
Patients with known inability to return for follow-up visits or obtain follow-up studies required to assess for toxicity to therapy will be excluded
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Patients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
Ability to attend required study visits and return for adequate follow up, as required by this protocol
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Patients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy; telemedicine visits are acceptable
Ability to return to Duke University Medical Center for adequate follow-up, as required by this protocol
Agree to follow protocol required evaluations
Patients must be able to return to surgical facility for  and/or  day (+/-  days) follow up appointment
Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to device usage plan, other study procedures, and study restrictions
Able to return for treatment and follow-up as specified in the protocol
Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Patients must be willing to return to the clinic for follow-up visits
Willing to return to participating medical institutions for follow-up
Must agree to follow pregnancy precautions as required by protocol.
Inability to Participate Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
Ability to attend required study visits and return for adequate follow up, as required by this protocol
Agree to return for all follow-up evaluations and procedures specified in the protocol
Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Willingness to return to University of Maryland Greenebaum Cancer Center (UMGCC) or other participating institutions for treatment and follow-up
Subjects with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Ability to return to Duke University Medical Center for adequate follow-up as required by this protocol
Ability to provide informed consent, and to return to clinic for adequate follow-up for the period that the protocol requires
The subject must be willing to return to the study center for vaccinations and study-related follow up procedures including blood and tumor collections and completion of imaging studies as required by the protocol.
Must agree to follow pregnancy precautions as required by the protocol.
Inability to return for follow-up visits or obtain follow-up studies required to assess toxicity and response to therapy
Patients who are unable to return for follow-up visits as required by this study
RECURRENT/ PROGRESSIVE DIPG (STRATUM ): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
NON-PROGRESSED DIPG (STRATUM ): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
Agreement to return for the trial required follow-up visits
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Able to follow instructions
Unable to return for follow-up visits and tests
Subjects, who, in the opinion of the clinical Investigator, are able to understand this clinical investigation, cooperate with the investigational procedures and are willing to return for all the required post-treatment follow-up visits
Return for follow-up visits
Patients must be willing to return to National Institutes of Health (NIH) for follow-up
